A distinct mechanism
of action1
The first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist to reverse pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.1
How RYZUMVI works1,2:
RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle and indirectly reverses the effects of muscarinic antagonists on the iris sphincter muscle, thus reducing pupil size after dilation.1
For illustrative purposes only.
Select a dilating agent used in RYZUMVI clinical trials to learn more
RYZUMVI reversed pupil dilation regardless of whether phenylephrine, tropicamide, or Paremyd® (hydroxyamphetamine hydrobromide and tropicamide) was used.1,8,9